Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00211939 · ClinicalTrials.gov registry record · Phase 4
CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients
A Phase 4 study of Arteriosclerosis and Calcinosis, sponsored by Nabi Biopharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 203
- Enrollment target
- 1
- Study location
NCT00211939: Completed Phase 4 study of Arteriosclerosis and Calcinosis, sponsored by Nabi Biopharmaceuticals.
NCT00211939 is a Phase 4 study of Arteriosclerosis and Calcinosis that has completed, run by Nabi Biopharmaceuticals. The registered enrollment target is 203 participants, below the 3,120-participant average among 5 other Arteriosclerosis trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00211939, a Phase 4 study of Arteriosclerosis and Calcinosis, has completed, sponsored by Nabi Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 203 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate the effects of two phosphate binders, PhosLo and sevelamer, on heart calcification in dialysis patients. The study will use a non-invasive technique, electron beam computed tomography (CT) scanning, to measure calcium in the coronary arteries, the aortic valve, and the mitral valve.
Conditions Studied
Interventions
- DRUG atorvastatin
- DRUG calcium acetate
- DRUG sevelamer
Study Locations (1)
Texas
- University of Texas Health Sciences Center - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2005-01 |
| Est. Completion | 2007-03 |
| Phase | Phase 4 |
What the finished NCT00211939 record still lists
NCT00211939 is an interventional study that assigns participants to a tested intervention. The registered 203 participants enrollment target is mid-sized for trials with a published cap, below the 3,120-participant average among 5 other Arteriosclerosis trials with a reported enrollment target (93% lower).
The record links to 3 conditions, with Arteriosclerosis appearing as the primary indexed condition, and to 3 interventions - of which atorvastatin is the first listed.
NCT00211939 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00211939 about?
NCT00211939 is a clinical study titled "CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients". The purpose of the study is to evaluate the effects of two phosphate binders, PhosLo and sevelamer, on heart calcification in dialysis patients. The study will use a non-invasive technique, electron beam computed tomography (CT) scanning, to measure calcium in the coronary arteries, the aortic valve...
What is the current status of trial NCT00211939?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 203 participants. The study started on 2005-01. Estimated completion is 2007-03.
What conditions does trial NCT00211939 study?
This clinical trial studies the following conditions: Arteriosclerosis, Calcinosis, Hyperparathyroidism, Secondary.
What interventions are being tested in trial NCT00211939?
The interventions under investigation include: atorvastatin (DRUG), calcium acetate (DRUG), sevelamer (DRUG).
Who is sponsoring clinical trial NCT00211939?
This trial is sponsored by Nabi Biopharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00211939 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arteriosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium (The Optimal Trial)
RECRUITING · NA
-
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
ACTIVE NOT RECRUITING · Phase 3
-
Sapphire 3 CTO Study
COMPLETED · NA
-
Distributed Registry
COMPLETED
-
A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05652686 · 203 participants · Phase 1
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- NCT06063122 · 203 participants · NA
Development of a Therapeutic Device to Improve Speech Sound Differentiation in Preterm Infants
- NCT07031245 · 203 participants · NA
Evidence-Based Quality Improvement to Reduce VA Primary Care Burnout
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia